October 22, 2009Internal Medicine Journal
Prevalence and predictors of premature discontinuation of dual antiplatelet therapy after drug‐eluting stent implantation: importance of social factors in Asian patients
Key result
Living alone linked to a ~39% higher absolute rate of premature DAPT discontinuation post-DES.
- P=0.001
- n=207
Why the study?
What are the prevalence and predictors of premature discontinuation of dual antiplatelet therapy after drug-eluting stent implantation in Asian patients?
Population
207 consecutive Asian patients who underwent drug-eluting stent implantation at a single institution.
Design
Cohort
Follow-up
1 year
Authors
Discussion
Loading...
Member takes
Implication
Patients living alone may need adherence support after DES; observational data leave open whether interventions improve persistence.
Study Design
Type
Cohort (n=207)
Multicenter
No
Structured PICO
What are the prevalence and predictors of premature discontinuation of dual antiplatelet therapy after drug-eluting stent implantation in Asian patients?
P
Population
207 consecutive Asian patients who underwent drug-eluting stent implantation, followed for 1 year to assess premature discontinuation of antiplatelet therapy.
E
Exposure
Dual antiplatelet therapy (aspirin and clopidogrel)
O
Outcome
Premature discontinuation of antiplatelet therapy (defined as omission of aspirin and/or clopidogrel for 1 week or more) at 1 year
Main Result
Absolute Event Rate: 50% vs 11.3%
p-value: p=0.001
Living alone is a strong independent predictor of premature discontinuation of dual antiplatelet therapy after drug-eluting stent implantation in Asian patients, highlighting the importance of social factors in medication adherence.
Cite This Study
Poh et al. (2009) conducted a cohort in Drug-eluting stent implantation (n=207). Living alone vs. Not living alone was evaluated on Premature discontinuation of dual antiplatelet therapy (p=0.001). Living alone was associated with a significantly higher rate of premature discontinuation of dual antiplatelet therapy within 12 months after drug-eluting stent implantation (50.0% vs 11.3%, P=0.001).